Merck To Get Chronic Cough P2X3 Inhibitor Candidate With Afferent Buy
A candidate for chronic cough is one of the assets Merck & Co. will get by buying P2X3 inhibitor specialist Afferent Pharmaceuticals Inc, a US-based biotech focusing on chronic pain therapies caused when certain nerves become hypersensitive.
You may also be interested in...
New data puts Merck & Co's P2X3 receptor antagonist ahead of the field but Bellus Health's rival in the class may benefit from issues over taste alteration with gefapixant.
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.